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Background: There is a gap between evidence and practice in the
management of cardiovascular (CV) risk. Previous research indicated
benefits from community-based, multi-faceted interventions to screen,
diagnose, and manage CV risk in people with hypertension.
Methods: The Heart Outcomes Prevention and Evaluation 4 Canada
pilot study (HOPE 4) was a quasi-experimental preepost interventional
study, involving one community each in Hamilton, Ontario and Surrey,
British Columbia, Canada. Individuals aged 50 years with newly
diagnosed or poorly controlled hypertension were included. The inter-
vention was comprised of: (i) simplified diagnostic/treatment algo-
rithms implemented by community health workers (firefighters inReceived for publication August 26, 2020. Accepted October 5, 2020.
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Contexte : Il existe un ecart entre les donnees probantes et la pratique
en matière de prise en charge du risque cardiovasculaire (CV). Les
resultats d’etudes anterieures montrent que des interventions à volets
multiples en milieu communautaire visant à depister, à diagnostiquer
et à prendre en charge le risque CV chez les personnes atteintes
d’hypertension peuvent être benefiques.
Methodologie : L’etude pilote HOPE4 (Heart Outcomes Prevention and
Evaluation 4 Canada) etait une etude interventionnelle quasi experi-
mentale evaluant des patients avant et après certaines interventions,
menee au sein de deux communautes canadiennes, l’une situee à
Hamilton, en Ontario et l’autre à Surrey, en Colombie-Britannique.Cardiovascular disease (CVD) affects half of all individuals
during their lifetime.1-3 Multiple modifiable risk factors
contribute to its development, with hypertension the most
significant.4 Unfortunately, there are significant evidence-practice gaps in detection and management of established
CVD and its risk factors everywhere.5,6 For example, despite
clear evidence for the benefits of blood pressure (BP) reduc-
tion and the availability of low-cost and safe medication,7Corresponding author: Dr Jon-David Schwalm, Population Health
Research Institute, Hamilton General Hospital Campus, DBCVSRI, 237
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British Columbia and community health workers in Ontario) guided by
decision support and counselling software; (ii) recommendations for
evidence-based CV medications and lifestyle modifications; and (iii)
support from family/friends to promote healthy behaviours. The
intervention was developed as part of the international Heart Out-
comes Prevention and Evaluation 4 Canada pilot study trial and
adapted to the Canadian context. The primary outcome was the
change in Framingham Risk Score 10-year CV disease risk estimate
between baseline and 6 months.
Results: Between 2016 and 2017, a total of 193 participants were
screened, with 37 enrolled in Surrey, and 19 in Hamilton. Mean age
was 69 years (standard deviation 11), with 54% female, 27% diabetic,
and 73% with a history of hypertension. An 82% follow-up level had
been obtained at 6 months. Compared to baseline, there were sig-
nificant improvements in the Framingham Risk Score 10-year risk
estimate (30.6% vs 24.7%, P < 0.01), and systolic blood pressure
(153.1 vs 136.7 mm Hg, P < 0.01). No significant changes in lipids or
healthy behaviours were noted.
Conclusions: A comprehensive approach to health care delivery, using
a community-based intervention with community health workers,
supported by mobile-health technologies, has the potential to signifi-
cantly reduce cardiovascular risk, but further evaluation is warranted.
L’etude reunissait des participants âges de 50 ans ou plus venant de
recevoir un diagnostic d’hypertension ou souffrant d’hypertension mal
maîtrisee. Les interventions comprenaient : i) l’utilisation d’algo-
rithmes de diagnostic et de traitement simplifies par les intervenants
en sante du milieu communautaire (pompiers en Colombie-
Britannique et agents de sante communautaire en Ontario), à l’aide
d’un logiciel d’aide à la decision et de counselling; ii) la formulation de
recommandations fondees sur des donnees probantes concernant la
prise de medicaments et l’adoption d’habitudes de vie favorisant la
sante CV; et iii) la sollicitation du soutien des membres de la famille et
des amis afin de promouvoir l’adoption de comportements favorisant
la sante. Ces interventions ont ete mises au point dans le cadre de
l’etude pilote internationale HOPE4 et adaptees au contexte canadien.
Le critère d’evaluation principal etait la variation du score de risque de
Framingham, qui estime le risque de maladie CV à 10 ans, entre le
debut et le 6e mois de l’etude.
Resultats : De 2016 à 2017, un nombre total de 193 participants ont
ete soumis au processus de selection; 37 patients du centre de Surrey
et 19 patients du centre de Hamilton ont ete admis à l’etude. L’âge
moyen des participants etait de 69 ans (ecart-type : 11 ans); 54 %
d’entre eux etaient des femmes, 27 % etaient atteints de diabète et
73 % avaient des antecedents d’hypertension. Au 6e mois, 82 % des
sujets participaient toujours à l’etude. Des ameliorations significatives
ont ete observees comparativement au placebo en ce qui concerne le
score de risque de Framingham estimant le risque à 10 ans (30,6 % vs
24,7 %, p < 0,01) et la pression arterielle systolique (153,1 vs 136,7
mmHg, p < 0,01). Aucune variation significative n’a ete observee
quant à la lipidemie ou aux comportements favorisant la sante.
Conclusions : Une approche exhaustive de la prestation des soins de
sante reposant sur des interventions de la part des agents de sante
communautaire au moyen de technologies de sante mobiles pourrait
aider à reduire significativement le risque CV; une evaluation plus
poussee est toutefois necessaire.
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Volume 3 2021most hypertensive individuals are undetected, undertreated, or
poorly controlled, with as few as 18% achieving control in
high-income countries, as reported in the Population Urban
Rural Epidemiologic (PURE) study.8-10
Barriers to CVD prevention occur at the patient, health
care provider, and health system levels.11-16 Unfortunately,
people often lack awareness of their condition, and limited
access to care can contribute to low treatment rates and poor
adherence to medication and recommended lifestyle
changes.17 Furthermore, there are few approaches supported
by evidence for screening CVD risk, and few systematic efforts
to enhance adherence to treatment or to educate patients.
Current algorithms to initiate medication are often complex
and impractical, and many existing guidelines neglect the role
of other CVD risk factors beyond BP.18 Community health
workers (CHWs) can address several barriers to CVD risk
detection and management. A recent systematic review has
highlighted the benefit of task sharing between physicians and
CHWs with respect to the screening, diagnosis, and man-
agement of hypertension.19 Most published evidence is
derived from middle- and low-resource settings; however,
community-based CHWs may also have significant impact in
low-resource settings within high-income countries.
The primary objective of the Heart Outcomes Preven-
tion and Evaluation 4 (HOPE 4) Canada pilot study was to
develop and pilot a community-based, multifacetedintervention package provided by non-physician health
workers to improve long-term CVD risk in people with
hypertension, by addressing barriers identified in a detailed
assessment of the experiences of those with hypertension in
each context at the patient, health care provider, and health
system levels.Methods
Study design and community selection
The HOPE 4 Canada pilot study is a community-based,
preepost interventional study involving communities in
Hamilton, Ontario (ON) and Surrey, British Columbia (BC),
Canada. The city of Surrey, BC has a population of approx-
imately 500,000, of whom 20% live in the lowest quintile of
socioeconomic status, and where hypertension has a preva-
lence of 21.7% (3.4% greater than the provincial
average).20,21 The city of Hamilton, ON has a population of
approximately 600,000, with 15% of individuals living in
poverty.22 The prevalence of hypertension in Hamilton ap-
proaches 18%.23
Participant selection
Screening to identify eligible participants involved a com-
bination of household sampling and the use of community
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HOPE 4 Canada Pilot Studyoutreach centres or events based within public spaces, as
appropriate to the community. For this screening, medical
clinics (eg, primary care physician offices or hypertension
clinics) were purposely avoided. Participants were considered
eligible if they were aged 50 years with at least ONE of the
following criteria: (i) systolic blood pressure (SBP) 160 mm
Hg was recorded at 1 visit; (ii) SBP 140-159 mm Hg was
recorded in 1 visit AND participant reported a medical
diagnosis of hypertension or was taking anthypertensive
medication; (iii) SBP  130 mm Hg was recorded in 1 visit
AND participant reported a medical diagnosis of diabetes or
was taking medication for diabetes; (iv) participants did not
meet criteria 1-3, but SBP of 140-159 mm Hg was recorded
on 2 separate visits at least 24 hours apart. Blood pressure was
measured using 3 separate readings, in which the last 2 were
averaged to ensure consistency of recordings, and an auto-
mated Omron monitor was used at each visit. All screened
participants provided written consent, and all enrolled par-
ticipants provided full informed written consent. The study
was approved by the Hamilton Integrated Research Ethics
Board (#13-437) and the Simon Fraser University Research
Ethics Board (#H15-01233).
Participants were considered ineligible for this study if they
(i) refused to consent; (ii) were concurrently participating in
any other study or heart health program that would
compromise the protocol of the HOPE 4 Canada pilot study
at the time of enrollment; (iii) had a severe comorbid condi-
tion with life expectancy <1 year; or (iv) had other medical
serious condition(s) or factors likely to interfere with study
participation or with their ability to complete the trial.
Intervention
Although the HOPE 4 Canada pilot study has foundations
similar to those of the larger HOPE 4 multi-centre, cluster
randomized controlled trial (RCT) in Colombia and Malaysia, it
has a different design, and a modification of the intervention.24
The development and justification of the HOPE 4 international
RCT intervention has been published previously.24 Following
screening (Supplemental Appendices S1 and S2), participants in
the HOPE 4 Canada pilot study received a tailored multifaceted
intervention package designed to address identified barriers at
the patient, health care provider, and health system level.25-28
This package was modified from the HOPE 4 International
RCT and entails: (i) detection, treatment, and control of CVD
risk factors by CHWs in the community, who use tablet-based
simplified management algorithms, decision support, and
counseling programs; and (ii) support from a participant-
nominated treatment supporter (either a friend or family
member; Fig. 1). Details of the 1-week CHW training curric-
ulum, which was developed and piloted in Canada, have been
reported previously.29 Following baseline assessment and
counseling, participants were seen by CHWs at 4-6 weeks, 10-
14 weeks, and the final 6-month follow-up.
Although the HOPE 4 international cluster RCT used a
strategy similar to the one implemented in Canada, it is
essential to note that each intervention package was adapted
following an assessment of the local context. For example, in
Canada, the HOPE 4 pilot study focused on identifying high-
risk individuals within the community and connecting them
to existing services and programs. CHWs were responsible foridentifying participants with new or poorly controlled hy-
pertension and then recommending an evidence-based man-
agement strategy of antihypertensive medications and a statin,
to both participants and their primary care physician
(Supplemental Appendix S3).30 Furthermore, the CHWs
provided counselling regarding health lifestyle behaviours,
including diet, exercise, medication adherence, and smoking
cessation.24 Given that access to medications for CVD risk
reduction was considered to be less of a barrier, compared to
the accessibility in low- and middle-income countries,
particularly for those aged  65 years (where public drug
funding through PharmaCare, and BC and Ontario Drug
Benefit is available), medications were not provided as part of
the intervention in this Canadian pilot study.
To promote sustainability of the program, and consistency
with the core element of the intervention, adaptation to local
context and existing infrastructure was used when possible. In
Surrey, the HOPE 4 Canada pilot study utilized the existing
Surrey Fire Service’s community fire check safety program,
which involved household screening for hazards in vulnerable
households and neighborhoods. By leveraging this existing
program and the enthusiastic support of the Surrey Fire Chief
(L. Garis), community-based firefighters were trained to
implement the intervention package as non-physician health
workers. In Hamilton, the Urban Core Community Health
Centre was the central hub within a low-resource setting.
Individuals without any formal health care training but who
were associated with the Community Health Centre were
recruited as CHWs in Hamilton.
Outcomes
The primary outcome was the mean difference in the Fra-
mingham Risk Score (FRS) change from baseline to 6 months,
presented as the FRS 10-year risk estimate. Given the potential
for detection bias during the study follow-up, the development
of a new diagnosis of diabetes after the initial screening assess-
ment did not factor into the FRS calculations at 6 months. The
validated FRS was chosen as the primary outcome because it
includes multiple CVD risk factors (ie, blood pressure, smoking,
cholesterol) targeted by the intervention.31
Secondary outcomes included the change from baseline to
6 months in: (i) SBP; (ii) proportion of participants with well-
controlled SBP (ie, 140 mm Hg); (iii) low-density lipo-
protein (LDL), high-density lipoprotein, total cholesterol,
triglycerides, and glucose; (iv) smoking status; (v) physical
activity; and (vi) proportion of participants receiving 2 or
more antihypertensives and a statin.
Analysis
Continuous variables are reported as mean and standard
deviation. Categorical variables are reported as number and
percentage of participants corresponding to each category.
Baseline and 6-month data were compared using the paired t-
test for continuous measures, and McNemar's test for cate-
gorical measures. As the sample size of this study was small,
and participants were recruited opportunistically from
household and community settings, P-values reported in this
article need to be interpreted with caution. All analyses were
conducted using SAS version 9.2
Figure 1. Heart Outcomes Prevention and Evaluation 4 (HOPE 4) Canada pilot study intervention strategies to address barriers to cardiovascular
(CV) disease risk reduction. CHW, community health worker.
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Between January 2016 and November 2017, a total of
193 participants were screened for participation. Of these,
104 were ineligible, and 87 were invited to participate. A
total of 56 participants provided informed consent (37 in
Surrey, and 19 in Hamilton; Fig. 2). Table 1 outlines the
baseline characteristics of the study participants. The mean
age was 69 years (standard deviation 11), with 54% female,
27% diabetic, 73% with a history of hypertension, 7% with
prior myocardial infarction, and 9% with a prior stroke
(Table 1). Follow-up was obtained at 6 months in 82% of
participants (n ¼ 46). There were no significant differences
in baseline characteristics between those lost to follow-up
and those completing follow-up at 6 months.
Compared to baseline, there was a significant improvement
in the FRS 10-year risk estimate (30.6% vs 24.7%, P < 0.01),
SBP (153.1 vs 136.7 mm Hg, P < 0.01), and proportion of
participants with controlled SBP (5.6% vs 56.5%, P < 0.01).
No significant changes in lipids, smoking status, or physical
activity were noted. There was a significant increase in use of 2
or more antihypertensive medications (54.5% vs 68.6%, P ¼
0.01) and statins (40.7% vs 52.2%, P ¼ 0.01) at 6 months
compared to baseline (Table 2).Discussion
This pilot study suggests that a contextually appropriate,
community-based, multifaceted intervention package pro-
vided by CHWs can reduce CVD risk within a high-income
country, primarily through improvements in blood pressure
level.
The HOPE 4 Canada pilot study combined multiple
strategies to achieve these results. First, we have demonstrated
that with proper training and oversight, individuals with
minimal to no experience in health promotion can learn to use
a tablet-based decision support system to effectively identify,
educate, and counsel participants about their CVD risk.
Second, the HOPE 4 Canada pilot study intervention was
informed by an extensive barrier-to-care analysis.25-28 Third,
our study used a community-based intervention in which
participants were recruited from their homes or community-
outreach events. This approach was intended to help over-
come the traditionally low detection of hypertension in
community settings. Fourth, the HOPE 4 Canada interven-
tion involved task sharing among CHWs and physicians, as
recommended by the World Health Organization.32,33 This
strategy addresses health system barriers relating to both
Figure 2. Participant recruitment in Surrey, British Columbia, and Hamilton, Ontario, Canada.
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HOPE 4 Canada Pilot Studyphysician shortages and the time limitations of health care
providers for education and counseling. Fifth, this study
overcame medication-related barriers to the community
management of CVD risk. The HOPE 4 strategy included
recommendations to primary care providers (via participants)
that support the rapid and simplified initiation of combina-
tions of low doses of antihypertensive agents, an approach
endorsed by several guidelines.34-37 Statins were recom-
mended to all patients, as the evidence supports their use in
individuals with hypertension, regardless of lipid
concentrations.38-42 Finally, the HOPE 4 intervention
actively encouraged the involvement of participants’ families
and/or friends as treatment supporters of the management of
their CVD risk. This strategy has been shown to be effective at
improving medication adherence and even mortality in other
chronic conditions.43 Adaptation of this health system inter-
vention package to a high-income country shows promise per
the results of this pilot study.
The growing global burden of poorly managed hyperten-
sion and CVD strongly indicates the need for a markedly
different approach to controlling CVD risk. Task sharing with
non-physician health workers has been demonstrated to be
effective in low- and middle-income countries. A recentsystematic review of task sharing with non-physician health
workers for the management of BP reported reductions in
SBP by a mean of 4.8 mm Hg (95% confidence interval 3.6-
6.1).19 Although the majority of non-physician health workers
in this review were nurses (30 of 63), 30% were CHWs,
similar to those in the HOPE 4 Canada pilot study. The
recently published international HOPE 4 international RCT
demonstrated that a comprehensive model of care led by
CHWs substantially improved BP control and CVD risk.44
This open, community-based, cluster RCT involved 1371
individuals with new or poorly controlled hypertension, from
30 communities in Colombia and Malaysia. There was an
absolute 11.5 mm Hg greater reduction in SBP, and a 0.4
mmol/L greater reduction in LDL with the intervention group
(both P < 0.0001). Change in blood pressure control status
(<140 mm Hg) was 69% in the intervention group vs 30% in
the control group (P < 0.0001). The HOPE 4 international
RCT achieved a much greater reduction in hypertension than
that observed in the systematic review, suggesting that our
protocol is particularly effective. The World Health Organi-
zation’s Heart Failure Etiology and Analysis Research Team
(HEART) technical package employs a similar training cur-
riculum for non-physician health workers and supports task
Table 1. Baseline characteristics of the study participants
Characteristic Overall Surrey Hamilton
Number of subjects 56 37 19
Age, y (mean, SD) 69.3 (10.5) 73.6 (8.38) 61.0 (9.25)
Women 30 (53.6) 19 (51.4) 11 (57.9)
Education
None/primary/unknown 7 (12.5) 2 (5.4) 5 (26.3)
Secondary/high school 24 (42.9) 18 (48.6) 6 (31.6)
Trade/college/university 25 (44.6) 17 (45.9) 8 (42.1)
Past medical history (self-reported)
Current smoker 8 (14.3) 3 (8.1) 5 (26.3)
Among women 1 (3.3) 0 (0.0) 1 (9.1)
Among men 7 (26.9) 3 (16.7) 4 (50.0)
Diabetes 15 (26.8) 7 (18.9) 8 (42.1)
History of hypertension 41 (73.2) 27 (73.0) 14 (73.7)
Atrial fibrillation 7 (12.5) 6 (16.2) 1(5.3)
Stroke 5 (8.9) 3 (8.1) 2 (10.5)
Myocardial infarction 4 (7.1) 1 (2.7) 3 (15.8)
Angina 5 (8.9) 4 (10.8) 1 (5.3)
Congestive heart failure 1 (1.8) 1 (2.7) 0
Liver disease 1 (1.8) 0 1 (5.3)
Kidney disease 2 (3.6) 2 (5.4) 0
Values are n (%), unless otherwise indicated.
SD, standard deviation.
-25 -20 -15 -10 -5 0
HOPE4 Interna onal-Control
HOPE4 Interna onal-Interven on
HOPE4 Canada
SBP (mmHg) FRS (% 10-year risk es mate)
Figure 3. Comparison of absolute reductions in systolic blood pres-
sure (SBP) and Framingham Risk Score (FRS) 10-year risk estimate
between the intervention and control groups of the international Heart
Outcomes Prevention and Evaluation 4 (HOPE 4) study and the HOPE
4 Canada pilot study.
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ment.29 In further support of the HOPE 4 approach, the
PolyIran RCT demonstrated that an intervention comprised
of community screening with CHWs and the use of a single
polypill (combination antihypertensives with a statin) resulted
in significant reductions in cardiovascular events as compared
to usual care.45
Our current Canadian pilot study expands on these data to
explore the feasibility of the intervention package, including
task sharing, in a high-income country. Three RCTs also sup-
port components of theHOPE 4 health system interventions inTable 2. Change in outcomes between baseline and 6 months in





(n ¼ 46) P*
FRS 10-year risk estimate, mean (SD) 30.6 (18.1) 24.7 (17.0) < 0 .01
Current smokery 8 (14.8) 5 (10.9) d
Physically active 25 (46.3) 28 (60.9) 0.11
Use of BP-lowering medications 37 (68.5) 35 (76.1) 0.10
Use of one BP-lowering medication 17 (45.9) 11 (31.4) 0.01
Use of  2 BP-lowering medications 20 (54.5) 24 (68.6) 0.01
SBP, mm Hg, mean (SD) 153.1 (12.1) 136.7 (15.7) < 0.01
Controlled SBP, < 140 mm Hg 3 (5.6) 26 (56.5) < 0.01
Use of statins 22 (40.7) 24 (52.2) 0.01
Total cholesterol, mmol/L, mean (SD) 4.8 (1.3) 4.7 (1.1) 0.10
LDL, mmol/L, mean (SD) 2.7 (1.1) 2.7 (0.9) 0.15
HDL, (mmol/L), mean (SD) 1.4 (0.5) 1.4 (0.5) 0.15
Triglyceride, mmol/L, mean (SD) 1.6 (0.7) 1.6 (0.7) 0.20
Values are n (%), unless otherwise indicated.
BP, blood pressure; FRS, Framingham risk score; HDL, high-density
lipoprotein; HOPE, Heart Outcomes Prevention and Evaluation Canada
pilot study; LDL. low-density lipoprotein; SBP, systolic blood pressure; SD,
standard deviation.
* Based on paired subjects only, who had both baseline and 6 months
using paired t-test for continuous measures and McNemar’s test for categorical
measures.
yThere is no change in smoking status among 46 participants who had
both baseline and 6-month follow-up measures. As a result, P is not estimable
for this exposure.high-income countries. Muñoz et al. demonstrated the benefits
of a polypill (combination antihypertensives with a statin) to
reduce SBP and LDL, compared to usual care in a high-income
country, in a lower-income population.46A paramedic-led,
community-based health promotion program significantly
lowered the number of ambulance calls, increased the number
of quality-adjusted life years and ability to perform usual ac-
tivities, and lowered SBP, among older adults living in subsi-
dized housingwithin a high-income country.47 Finally, a cluster
RCT in a high-income country, involving volunteer-run car-
diovascular risk assessment and education sessions held in
community-based pharmacies, demonstrated a significant
reduction in cardiovascular morbidity.48 Although health care
systems differ among countries with different income levels,
there are substantial gaps in all countries that the components of
the HOPE 4 intervention can help address.
Limitations
Although the HOPE 4 Canada pilot study demonstrated a
significant reduction in the FRS 10-year risk estimate and
improved BP control, this was a small preepost pilot study,
focusing primarily on the feasibility of implementing the
intervention package within 2 communities in a high-income
country. Furthermore, there were no changes in LDL or
health behaviours. There was no control group, and our re-
sults could be influenced by regression to the mean.
However, our results in the HOPE 4 Canada pilot study
were similar to the differences observed in the international
HOPE 4 RCT, which was well-powered, had a randomized
control group, and demonstrated a similar level of benefit
with a similar intervention.44 The absolute reductions in
FRS and SBP in this Canadian cohort fall between the re-
ductions noted in the intervention and control groups of the
international HOPE 4 study (Fig. 3). This comparison
highlights the power of community screening and increased
participant awareness of personal CVD risk. This knowledge
likely drove the observed improvements in both the
Canadian cohort and the control group in the international
HOPE 4 study.
The HOPE 4 Canada pilot study had plans to expand to
multiple communities within BC using the firefighter model.
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examining their emergency responder roles and expanding
their community engagement.49 With the decline in tradi-
tional firefighting work, owing to improved safety practices
and building technologies, fire services have the potential to
address a variety of health and safety issues, including CVD
risk reduction. Furthermore, established door-to-door fire-
fighter community outreach programs offer opportunistic
screening for CVD risk. Unfortunately, due to the opioid
crisis in Western Canada, and related competing priorities, the
fire services could not continue their focus on CVD risk
reduction in Surrey, BC.50 Task sharing with firefighters as
CHWs was demonstrated to be feasible, but sustainability of
this model in a high-income setting proved to be the primary
challenge facing the HOPE 4 Canada pilot study. Firefighters,
paramedics, community pharmacists, and trained volunteers
all offer promise in community-based CVD risk reduction,
but there is a need to further evaluate their potential roles
within existing health care prevention models to ensure sus-
tainability and optimal impact.19,47,48Conclusions
Improvements in individual CVD risk factors from baseline
to 6-month follow-up in this health system strategy pilot study
were each modest. However, collectively, the impact led to a
significant reduction in the FRS 10-year risk estimate, which
translates into a 20% reduction in CVD risk. These results are
consistent with those of the larger HOPE 4 international cluster
RCT, suggesting that the HOPE 4 model of community-based
intervention involving CHWs may be applicable to high-
income countries. A comprehensive approach to healthcare de-
livery using a community-based intervention with CHWs, and
supported by mobile-health technologies, has the potential to
significantly reduce CVD risk in high-income countries, but
further evaluation is warranted.Acknowledgements
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